Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Polio Virus | Research

Malaria and the incidence of COVID-19 in Africa: an ecological study

Author: Farrokh Habibzadeh

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

It has been shown that stimulation of innate immunity may provide temporary protection against a variety of infectious diseases. Malaria has been shown to induce a robust innate immune response. This study was conducted to test the hypothesis that if the cumulative number of cases diagnosed with COVID-19 per 100,000 population was correlated with the prevalence of malaria in African countries where both malaria and COVID-19 were prevalent.

Methods

In this ecological study, the cumulative incidence of COVID-19 and the prevalence of malaria were compared in 53 African countries. A negative binomial regression analysis with the cumulative incidence of COVID-19 as the dependent variable, and the human development index (HDI) and the prevalence of malaria, as independent variables, were used.

Results

The mean cumulative incidence of COVID-19 was 522 cases per 100,000. Each 0.1 unit increase in HDI was associated with 2.4-fold (95% confidence interval 1.8–3.1) increase in the cumulative incidence of COVID-19. Prevalence of malaria was also independently associated with the cumulative incidence; each 10% increase in the prevalence was associated with 28% (10–41%) decrease in the cumulative incidence of COVID-19.

Conclusions

Malaria might protect people against SARS-CoV-2 through the stimulation of innate immunity. Stimulation of the innate immune system could be the first line of defense in the pandemic preparedness arsenal.
Appendix
Available only for authorised users
Literature
1.
go back to reference Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–88.CrossRef Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–88.CrossRef
2.
go back to reference Domínguez-Andrés J, dos Santos JC, Bekkering S, Mulder WJM, van der Meer JWM, Riksen NP, Joosten LAB, Netea MG. Trained immunity: adaptation within innate immune mechanisms. Physiol Rev. 2023;103(1):313–46.CrossRef Domínguez-Andrés J, dos Santos JC, Bekkering S, Mulder WJM, van der Meer JWM, Riksen NP, Joosten LAB, Netea MG. Trained immunity: adaptation within innate immune mechanisms. Physiol Rev. 2023;103(1):313–46.CrossRef
3.
go back to reference Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995;311(7003):481–5.CrossRef Aaby P, Samb B, Simondon F, Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. BMJ. 1995;311(7003):481–5.CrossRef
4.
go back to reference Habibzadeh F, Sajadi MM, Chumakov K, Yadollahie M, Kottilil S, Simi A, Stafford K, Saeidimehr S, Rafiei M, Gallo RC. COVID-19 infection among women in Iran exposed vs unexposed to children who received attenuated poliovirus used in oral polio vaccine. JAMA Netw Open. 2021;4(11): e2135044.CrossRef Habibzadeh F, Sajadi MM, Chumakov K, Yadollahie M, Kottilil S, Simi A, Stafford K, Saeidimehr S, Rafiei M, Gallo RC. COVID-19 infection among women in Iran exposed vs unexposed to children who received attenuated poliovirus used in oral polio vaccine. JAMA Netw Open. 2021;4(11): e2135044.CrossRef
5.
go back to reference Prentice S, Nassanga B, Webb EL, Akello F, Kiwudhu F, Akurut H, Elliott AM, Arts RJW, Netea MG, Dockrell HM, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021;21(7):993–1003.CrossRef Prentice S, Nassanga B, Webb EL, Akello F, Kiwudhu F, Akurut H, Elliott AM, Arts RJW, Netea MG, Dockrell HM, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021;21(7):993–1003.CrossRef
6.
go back to reference Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355: i5170.CrossRef Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355: i5170.CrossRef
7.
go back to reference Chumakov MP, Voroshilova MK, Antsupova AS, Boiko VM, Blinova MI, Priimiagi LS, Rodin VI, Seibil VB, Siniak KM, Smorodintsev AA, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992;11–12:37–40. Chumakov MP, Voroshilova MK, Antsupova AS, Boiko VM, Blinova MI, Priimiagi LS, Rodin VI, Seibil VB, Siniak KM, Smorodintsev AA, et al. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992;11–12:37–40.
8.
go back to reference Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989;36:191–202.
9.
go back to reference Habibzadeh F, Chumakov K, Sajadi MM, Yadollahie M, Stafford K, Simi A, Kottilil S, Hafizi-Rastani I, Gallo RC. Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE. 2022;17(3): e0265562.CrossRef Habibzadeh F, Chumakov K, Sajadi MM, Yadollahie M, Stafford K, Simi A, Kottilil S, Hafizi-Rastani I, Gallo RC. Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE. 2022;17(3): e0265562.CrossRef
10.
go back to reference Yagovkina NV, Zheleznov LM, Subbotina KA, Tsaan AA, Kozlovskaya LI, Gordeychuk IV, Korduban AK, Ivin YY, Kovpak AA, Piniaeva AN, et al. Vaccination with oral polio vaccine reduces COVID-19 incidence. Front Immunol. 2022;13: 907341.CrossRef Yagovkina NV, Zheleznov LM, Subbotina KA, Tsaan AA, Kozlovskaya LI, Gordeychuk IV, Korduban AK, Ivin YY, Kovpak AA, Piniaeva AN, et al. Vaccination with oral polio vaccine reduces COVID-19 incidence. Front Immunol. 2022;13: 907341.CrossRef
11.
go back to reference Habibzadeh F, Yadollahie M, Simi A. Use of oral polio vaccine and the global incidence of mother-to-child human immunodeficiency virus transmission. Front Public Health. 2022;10: 878298.CrossRef Habibzadeh F, Yadollahie M, Simi A. Use of oral polio vaccine and the global incidence of mother-to-child human immunodeficiency virus transmission. Front Public Health. 2022;10: 878298.CrossRef
12.
13.
go back to reference Schrum JE, Crabtree JN, Dobbs KR, Kiritsy MC, Reed GW, Gazzinelli RT, Netea MG, Kazura JW, Dent AE, Fitzgerald KA, et al. Cutting edge: Plasmodium falciparum induces trained innate immunity. J Immunol. 2018;200(4):1243–8.CrossRef Schrum JE, Crabtree JN, Dobbs KR, Kiritsy MC, Reed GW, Gazzinelli RT, Netea MG, Kazura JW, Dent AE, Fitzgerald KA, et al. Cutting edge: Plasmodium falciparum induces trained innate immunity. J Immunol. 2018;200(4):1243–8.CrossRef
17.
go back to reference Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, Webster S, Cameron-Blake E, Hallas L, Majumdar S, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat Hum Behav. 2021;5(4):529–38.CrossRef Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, Webster S, Cameron-Blake E, Hallas L, Majumdar S, et al. A global panel database of pandemic policies (Oxford COVID-19 government response tracker). Nat Hum Behav. 2021;5(4):529–38.CrossRef
20.
go back to reference Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, Alam U, Anyona M. What could explain the lower COVID-19 burden in Africa despite considerable circulation of the SARS-CoV-2 virus? Int J Environ Res Public Health. 2021;18(16):8638.CrossRef Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, Alam U, Anyona M. What could explain the lower COVID-19 burden in Africa despite considerable circulation of the SARS-CoV-2 virus? Int J Environ Res Public Health. 2021;18(16):8638.CrossRef
21.
go back to reference Gowda DC, Wu X. Parasite recognition and signaling mechanisms in innate immune responses to malaria. Front Immunol. 2018;9:3006.CrossRef Gowda DC, Wu X. Parasite recognition and signaling mechanisms in innate immune responses to malaria. Front Immunol. 2018;9:3006.CrossRef
Metadata
Title
Malaria and the incidence of COVID-19 in Africa: an ecological study
Author
Farrokh Habibzadeh
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08032-2

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine